- Home
- AUTL vs BOE Comparison
AUTL vs BOE Comparison
Compare AUTL & BOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- BOE
- Stock Information
- Founded
- AUTL 2014
- BOE 2005
- Country
- AUTL United Kingdom
- BOE United States
- Employees
- AUTL N/A
- BOE N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- BOE Trusts Except Educational Religious and Charitable
- Sector
- AUTL Health Care
- BOE Finance
- Exchange
- AUTL Nasdaq
- BOE Nasdaq
- Market Cap
- AUTL 625.4M
- BOE 634.0M
- IPO Year
- AUTL 2018
- BOE N/A
- Fundamental
- Price
- AUTL $2.40
- BOE $11.33
- Analyst Decision
- AUTL Strong Buy
- BOE
- Analyst Count
- AUTL 5
- BOE 0
- Target Price
- AUTL $9.32
- BOE N/A
- AVG Volume (30 Days)
- AUTL 1.6M
- BOE 166.1K
- Earning Date
- AUTL 08-12-2025
- BOE 01-01-0001
- Dividend Yield
- AUTL N/A
- BOE 7.30%
- EPS Growth
- AUTL N/A
- BOE N/A
- EPS
- AUTL N/A
- BOE N/A
- Revenue
- AUTL $9,011,000.00
- BOE N/A
- Revenue This Year
- AUTL $472.28
- BOE N/A
- Revenue Next Year
- AUTL $114.92
- BOE N/A
- P/E Ratio
- AUTL N/A
- BOE N/A
- Revenue Growth
- AUTL N/A
- BOE N/A
- 52 Week Low
- AUTL $1.11
- BOE $8.80
- 52 Week High
- AUTL $5.00
- BOE $10.48
- Technical
- Relative Strength Index (RSI)
- AUTL 50.28
- BOE 48.74
- Support Level
- AUTL $2.33
- BOE $11.25
- Resistance Level
- AUTL $2.60
- BOE $11.40
- Average True Range (ATR)
- AUTL 0.16
- BOE 0.10
- MACD
- AUTL -0.03
- BOE -0.01
- Stochastic Oscillator
- AUTL 18.92
- BOE 34.00
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest
Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.